The study was stopped when the original principal investigator moved to a new institution.

The goal of this study is to assess a slimy substance that settles/deposits along blood vessel wall. This slimy substance is called plaque. Plaque could be made up of fat, calcium or both. Plaque deposition narrows the vessels. This leads to decreased blood flow to various parts of body. Blood vessels include vessels that supply to heart (coronary), vessels to brain (carotid), vessels to kidneys (renal) and vessels to legs (femoral). Decreased blood flow causes symptoms such as brain stroke, heart attack, leg pain. Similarly individuals at risk of cardiovascular disease can have certain markers elevated in their blood that can be measured by simple blood tests.

High or increased plaque deposition is seen in neck vessels of cancer patients who received radiation to chest or head and neck as part of their cancer treatment. Cancer survivors are at increased risk of plaque development and are therefore called high-risk population. Exercise +/- fat lowering medicine can potentially decrease plaque deposition and statins are one of the several fat lowering medications.

Cardiovascular disease (CVD) and cancer are the leading causes of suffering and death amongst the American population. While an ever-increasing number of cancer survivors have a favorable outcome due to advances in cancer treatment; cancer survivors remain at high risk of developing CVD at an early age. There is scant information available on the pathogenic process that contributes to cardiovascular threat amongst cancer survivors and little is known about the interventions, which may interrupt or decrease the risk of CVD in this population. Importantly, early-subclinical markers may substantially precede clinical markers.

The objective of this project is to accurately determine the constituents and characteristics of atherosclerotic plaques in carotid arteries by magnetic resonance imaging (MRI) techniques in cancer survivors; at different data intervals: before and after administration of treatment (medical and life style modification) and then correlate contrast agent dynamics with serum markers of inflammation and other tests of cardiac or vascular dysfunction, where available.

The proposed study involves 100 asymptomatic patients who received prior chest or head and neck radiation therapy (HNXRT) as part of cancer treatment. MRI data (direct assessment of atherosclerosis) would be correlated with indirect measures of atherosclerosis (blood surrogate markers & metabolomics).

The investigators intend to conduct an initial baseline MRI, blood tests (to correlate with surrogate markers of inflammation) and other tests whenever available of cardiac or vascular dysfunction. This cohort will be followed up with medication and/or life style modification regimen for a period of initially18 months and subsequently at 36 months. A repeat of all baseline studies (MRI and blood tests) would be performed as part of the 18 and 36-month follow-up. The plaque characteristics found at MRI will be correlated with results of blood tests (baseline, 18 and 36 months) and changes in one or both will be the expected end point of the study.

Inclusion Criteria:

• Age 22 and above with prior head and neck or chest irradiation
• Six months or more post head and neck irradiation
• Documented subclinical cardiovascular disease (inflammatory markers in the serum)
• Pre-existing plaques (detected by ultrasound, CT or MRI)
• Asymptomatic major arterial stenosis
• Not being considered for arterial surgery or endovascular treatment.

Exclusion Criteria:

• Recurrence of cancer (with or without treatment)
• Planned surgical or endovascular intervention for revascularization of carotid arteries at the time of enrollment
• Renal failure
• Estimated glomerular filtration rate (eGFR) < 45 (calculation based on serum creatinine levels, race, age and gender)
• Medically unstable or hematologic, renal, or hepatic dysfunction
• Non-atherosclerotic arterial stenosis (dissection)
• Presence of stents or external clips that can cause artifacts impairing accurate interpretation of MRI data
• Contraindications to MRI: cardiac pacemaker, metal implants, metal in eyes, pregnant or nursing women, claustrophobia, allergy to MRI contrast
• Physical or mental impairment that would limit the patient's ability to comply with the medical instructions or study procedures

All participants who began the intervention are included in the baseline analysis population description.

Adverse events were collected from the time the participant signed the consent form through the duration of participation (up to 36 months).

All adverse events were graded as to their attribution (unrelated to protocol, or possibly, probably, or definitely related to protocol). All serious or unexpected adverse experiences and all deaths were recorded and reported according to the National Cancer Institute Common Toxicity Criteria. Serious adverse events were not expected to occur in this study due to the low risk involved with the study procedures performed.